168 results
S-8
EX-99.7
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the state of New York and agree that such litigation shall
S-8
EX-99.5
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
in the state of New York and agree that such litigation shall be conducted in the state courts of the state of New York or the federal courts
S-8
EX-99.6
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
, the parties hereby consent to exclusive jurisdiction in the state of New York and agree that such litigation shall be conducted in the state courts
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Other Events
7:37am
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks
8-K
EX-99.1
4fp1ck3wq 831
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
8-K
EX-99.2
rnn qvbrus4
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
6nw5kbpm1
18 Apr 24
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
3e0dfblpjndrcy096li
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
424B5
cxt8sq931e2chv4q
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
c3urpxc3 6svk
16 Apr 24
Automatic shelf registration
4:01pm
8-K
t9ye1x3aiabcr
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
ynmk50gdn10lv
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
1i8tm766p4
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
pdczr6 qr0sy
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am